NASDAQ:BDSX Biodesix (BDSX) Stock Price, News & Analysis $1.72 +0.06 (+3.61%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.68▼$1.7350-Day Range$1.30▼$1.7952-Week Range$1.03▼$2.21Volume58,941 shsAverage Volume149,128 shsMarket Capitalization$197.27 millionP/E RatioN/ADividend YieldN/APrice Target$3.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Biodesix alerts: Email Address Biodesix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside78.8% Upside$3.08 Price TargetShort InterestHealthy0.44% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 5 Articles This WeekInsider TradingSelling Shares$8,025 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.36) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.75 out of 5 starsMedical Sector281st out of 936 stocksMedical Laboratories Industry8th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingBiodesix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiodesix has only been the subject of 3 research reports in the past 90 days.Read more about Biodesix's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.44% of the outstanding shares of Biodesix have been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently decreased by 7.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiodesix does not currently pay a dividend.Dividend GrowthBiodesix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BDSX. Previous Next 4.1 News and Social Media Coverage News SentimentBiodesix has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Biodesix this week, compared to 1 article on an average week.Search Interest1 people have searched for BDSX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Biodesix to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,025.00 in company stock.Percentage Held by Insiders69.20% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.96% of the stock of Biodesix is held by institutions.Read more about Biodesix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biodesix are expected to grow in the coming year, from ($0.36) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biodesix is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biodesix is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiodesix has a P/B Ratio of 34.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biodesix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Biodesix Stock (NASDAQ:BDSX)Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Read More BDSX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDSX Stock News HeadlinesJune 18, 2024 | businesswire.comBiodesix Named to Inc. Magazine's 2024 “Best Workplaces”May 28, 2024 | businesswire.comBiodesix to Participate in Two Investor Conferences in JuneJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 21, 2024 | finance.yahoo.comBiodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual MeetingMay 13, 2024 | markets.businessinsider.comBuy Rating Justified by Biodesix’s Market Leadership and Strong Growth ProspectsMay 11, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Just Reported Earnings, And Analysts Cut Their Target PriceMay 10, 2024 | finance.yahoo.comBiodesix Inc (BDSX) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 PerformanceMay 10, 2024 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Call TranscriptJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 10, 2024 | finance.yahoo.comBiodesix First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | finance.yahoo.comBiodesix Inc (BDSX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 8, 2024 | investorplace.comBDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comBiodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule ManagementMay 7, 2024 | businesswire.comBiodesix to Participate in the 2024 RBCCM Global Healthcare ConferenceApril 24, 2024 | businesswire.comBiodesix to Report First Quarter 2024 Financial Results on May 8, 2024April 13, 2024 | finance.yahoo.comThe recent US$4.0m market cap decrease is likely to have disappointed insiders invested in Biodesix, Inc. (NASDAQ:BDSX)April 9, 2024 | businesswire.comBiodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual MeetingApril 5, 2024 | markets.businessinsider.comS&P 500 Gains Over 1%; GCT Semiconductor Shares Spike HigherSee More Headlines Receive BDSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:BDSX CUSIPN/A CIK1439725 Webwww.biodesix.com Phone303-417-0500FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$3.08 High Stock Price Target$3.50 Low Stock Price Target$2.80 Potential Upside/Downside+81.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,150,000.00 Net Margins-85.80% Pretax Margin-85.80% Return on Equity-29,379.44% Return on Assets-52.08% Debt Debt-to-Equity Ratio7.69 Current Ratio0.91 Quick Ratio0.91 Sales & Book Value Annual Sales$49.09 million Price / Sales3.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book34.13Miscellaneous Outstanding Shares114,690,000Free Float35,323,000Market Cap$195.70 million OptionableOptionable Beta1.21 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Scott Hutton (Age 52)President, CEO & Director Comp: $614.92kMs. Robin Harper Cowie (Age 44)CFO, Secretary & Treasurer Comp: $390.3kMr. Kieran O'Kane (Age 47)Chief Commercial Officer Comp: $392.61kDr. Heinrich RöderFounder & CTOMr. Christopher VazquezVP, Controller & Chief Accounting OfficerMr. Mark DeBlockVice President of SalesMr. Robbie LuntSenior Director of MarketingMs. Jessica OlbrichtSenior Director of Human ResourcesDr. Gary Anthony Pestano Ph.D. (Age 57)Chief Development Officer Ms. Bobbi CoffinChief Growth OfficerMore ExecutivesKey CompetitorsFulgent GeneticsNASDAQ:FLGTCelcuityNASDAQ:CELCCastle BiosciencesNASDAQ:CSTLGrailNASDAQ:GRALSera PrognosticsNASDAQ:SERAView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Bought 38,157 shares on 5/29/2024Ownership: 0.466%Oracle Investment Management Inc.Sold 30,588 shares on 5/15/2024Ownership: 0.026%Scott HuttonSold 3,764 sharesTotal: $5,570.72 ($1.48/share)Robin Harper CowieSold 980 sharesTotal: $1,450.40 ($1.48/share)Gary Anthony PestanoSold 434 sharesTotal: $642.32 ($1.48/share)View All Insider TransactionsView All Institutional Transactions BDSX Stock Analysis - Frequently Asked Questions How have BDSX shares performed this year? Biodesix's stock was trading at $1.84 on January 1st, 2024. Since then, BDSX stock has decreased by 6.5% and is now trading at $1.72. View the best growth stocks for 2024 here. How were Biodesix's earnings last quarter? Biodesix, Inc. (NASDAQ:BDSX) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. The company had revenue of $14.82 million for the quarter, compared to analyst estimates of $14 million. Biodesix had a negative net margin of 85.80% and a negative trailing twelve-month return on equity of 29,379.44%. When did Biodesix IPO? Biodesix (BDSX) raised $76 million in an initial public offering (IPO) on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. How do I buy shares of Biodesix? Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BDSX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodesix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.